Swedish Orphan Biovitrum AB's quarterly market cap
increased
from Sep. 2025 ($10,771 Mil) to Dec. 2025 ($12,306 Mil) and
increased
from Dec. 2025 ($12,306 Mil) to Mar. 2026 ($13,576 Mil).
Swedish Orphan Biovitrum AB's annual market cap
declined
from Dec. 2023 ($8,970 Mil) to Dec. 2024 ($8,758 Mil) but then
increased
from Dec. 2024 ($8,758 Mil) to Dec. 2025 ($12,306 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Swedish Orphan Biovitrum AB's Enterprise Value for Today is $17,951 Mil.
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Swedish Orphan Biovitrum AB Market Cap Related Terms
Swedish Orphan Biovitrum AB Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Market Cap distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Market Cap falls into.
Swedish Orphan Biovitrum AB Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (SWOBY) has a Market Cap of $16,033 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Swedish Orphan Biovitrum AB and its competitors. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #34 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 3.3%.
Is Swedish Orphan Biovitrum AB's Market Cap too high?
Swedish Orphan Biovitrum AB's current Market Cap is $16,033 Mil. The Drug Manufacturers industry median Market Cap is 207.38. Swedish Orphan Biovitrum AB's value of $16,033 Mil is 7631.3% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #34 out of 1023 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #34 out of 1023 companies for Market Cap. This places Swedish Orphan Biovitrum AB in the top 3% of its industry — outperforming the majority of peers. The industry median Market Cap is 207.38. Swedish Orphan Biovitrum AB's value of $16,033 Mil is 7631.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 207.38, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Market Cap of $16,033 Mil is 7631.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Market Cap is 207.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Market Cap is $16,033 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.17, compared to a current price of $23.18 — trading 35% above its estimated fair value. The current Market Cap is $16,033 Mil and 7631.3% above the Drug Manufacturers industry median of 207.38. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Market Cap is $16,033 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.18 is trading 35% above its estimated GF Value™ of $17.17.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
Market Cap: $16,033 Mil
GF Value™: $17.17 vs. price of $23.18 (35% above fair value)
Industry Position: 7631.3% above the Drug Manufacturers median (#34 of 1023)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
